Table 2. Univariate and multivariate analysis of baseline factors associated with 48 weeks of off-treatment HBe seroconversion and combined response among HBeAg-positive chronic hepatitis B.
| HBeAg-positive CHB patients (N = 118) | ||||||||
|---|---|---|---|---|---|---|---|---|
| HBe seroconversion* | Combined response* | |||||||
| Univariate | Multivariate | Univariate | Multivariate | |||||
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| Age (year) | 0.96 (0.92 ~ 1.01) | 0.158 | NA | 0.98 (0.94 ~ 1.04) | 0.536 | NA | ||
| Sex (male) (n/N=84/118) | 2.18 (0.85 ~ 5.61) | 0.105 | NA | 0.7 (0.25 ~ 1.92) | 0.492 | NA | ||
| Treatment naïve (%) (n/N = 84/118) | 0.71 (0.29 ~ 1.72) | 0.444 | NA | 0.96 (0.36 ~ 2.56) | 0.931 | NA | ||
| Treatment duration (weeks) | 0.96 (0. 91 ~ 1.01) | 0.136 | NA | 0.93 (0.85 ~ 1.02) | 0.115 | NA | ||
| ALT ≥200 U/L (n/N = 48/118) | 2.53 (1.08 ~ 5.9) | 0.032 | 2.46 (1.04 ~ 5.86) | 0.042 | 3.37 (1.31 ~ 8.72) | 0.012 | 2.44 (0.95 ~ 6.25) | 0.063 |
| HBsAg <250 IU/mL (n/N = 33/103) | 2.42 (0.98 ~ 5.97) | 0.054 | NA | 2.288 (1 ~ 5.23) | 0.05 | 2.67 (1.01 ~ 6.49) | 0.03 | |
| HBsAg <1,250 IU/mL (n/N = 45/103) | 1.42 (0.55 ~ 3.65) | 0.471 | NA | 4.57 (0.56 ~ 37.55) | 0.157 | NA | ||
| HBsAg <25,000 IU/mL (n/N = 93/103) | 10.45 (1.34 ~ 81.6) | 0.025 | 7.93 (0.99 ~ 63.68) | 0.051 | 6.41 (0.82 ~ 50.44) | 0.078 | NA | |
| HBV DNA <2.5 × 107 (IU/mL) (n/N = 59/118) | 1.3 (0.6 ~ 2.84) | 0.51 | NA | 2.66 (1.04 ~ 6.78) | 0.041 | 2.87 (1.27 ~ 6.5) | 0.011 | |
OR, Odds ratio; CI, confidence interval; NA, not adopted; NS, not significant; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
*Among 118 HBeAg-positive CHB patients, HBeAg seroconversion rate and the combined response rate were 31.4% (37/118) and 21.2% (25/118) at 48 weeks after EOT.